$3.58 0.0 0.0%
Last Trade - 22/01/21
| Market Cap | ÂŁ76.7m |
| Enterprise Value | ÂŁ29.9m |
| Revenue | ÂŁn/a |
| Position in Universe | 4796th / 6626 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.81 | 0.28 | 0.007 | 0.000 | 0.086 | 0.000 | 0.57 | -100.0% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | January 31, 2007 |
| Public Since | August 5, 2015 |
| No. of Shareholders: | 31 |
| No. of Employees: | 28 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Market |
| Shares in Issue | 29,439,175 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
As of 22/01/21, shares in Zynerba Pharmaceuticals Inc are trading at $3.58, giving the company a market capitalisation of ÂŁ76.7m. This share price information is delayed by 15 minutes.
Shares in Zynerba Pharmaceuticals Inc are currently trading at $3.58 and the price has moved by -37.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zynerba Pharmaceuticals Inc price has moved by -46.06% over the past year.
Of the analysts with advisory recommendations for Zynerba Pharmaceuticals Inc, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zynerba Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Zynerba Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Zynerba Pharmaceuticals Inc does not currently pay a dividend.
Zynerba Pharmaceuticals Inc does not currently pay a dividend.
Zynerba Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Zynerba Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Zynerba Pharmaceuticals Inc are currently trading at $3.58, giving the company a market capitalisation of ÂŁ76.7m.
Here are the trading details for Zynerba Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Zynerba Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Zynerba Pharmaceuticals Inc are currently priced at $3.58. At that level they are trading at 0.107% discount to the analyst consensus target price of 0.00.
Analysts covering Zynerba Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.913 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zynerba Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -15.66%. At the current price of $3.58, shares in Zynerba Pharmaceuticals Inc are trading at -11.37% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Zynerba Pharmaceuticals Inc based on the size of their shareholding:
